Skip to main content
Premium Trial:

Request an Annual Quote

VA Awards Akesogen $7.5M to Genotype US Military Veterans

NEW YORK (GenomeWeb News) – Akesogen today announced the US Department of Veterans Affairs has awarded the company a five-year, $7.5 million contract to genotype samples from US military veterans as part of the Million Veteran Program.

In the first year of the contract, Akesogen, a genomics and biorepository firm based in Norcross, Ga., will use a custom designed array-based genotyping product from Affymetrix to genotype 105,000 veterans, it said.

The Million Veteran Program was launched in 2011 in order to uncover the genetic basis of diseases with the aim of improving the health of those who have served in the US armed forces, as well as the larger population. More than 240,000 veterans have enrolled in the program to date, and during the next five to six years, up to 1 million veterans are anticipated to enroll in the VA study, Akesogen said.

In the fall, the VA also awarded a five-year $7.5 million contract to the BioProcessing Solutions Alliance to genotype 100,000 DNA samples from US veterans for the Million Veteran Program, as BioArray News reported. Affymetrix's arrays are also being used for research as part of that contract.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.